



Parkinson's Disease Center and Movement Disorders Clinic

Department of Neurology, Baylor College of Medicine, Houston, Texas

For more information please visit: www.jankovic.org



Baylor College of Medicine

BACKGROUND

The Parkinson's Disease Center and Movement Disorders Clinic (PDCMDC) at Baylor College of Medicine has long been recognized as one of the world's leading clinical and research institutions focusing on Parkinson's disease and other movement disorders. Founded by Joseph Jankovic, MD in 1977, the PDCMDC provides an unparalleled setting for treatment, research and education, with the ultimate goal of finding a cause and a cure for Parkinson's disease and other neurodegenerative and movement disorders. Our faculty includes Dr. Jankovic, Professor of Neurology and Distinguished Chair in Movement Disorders, and Director of the PDCMDC, Joohi Jimenez-Shahed, MD, Assistant Professor of Neurology, Arjun Tarakad, MD, Instructor of Neurology, Joshua Shulman, MD, PhD, Assistant Professor of Neurology, and Christine Hunter, RN, BSN, Instructor of Neurology and Director of Clinical Research.

MISSION STATEMENT

The primary missions of the PDCMDC are:

- To provide the most professional, compassionate patient care;
- To initiate and conduct clinical and basic research which upholds the highest scientific standards;
- To train physicians and other health care professionals to become skilled in the recognition and treatment of Parkinson's and other movement disorders and to inspire them to pursue basic or clinical research in the area of movement and neurodegenerative disorders.

CENTER OF EXCELLENCE

The PDCMDC generates 12,000 patient visits per year, yielding a database of 35,000+ individual patients, along with video and genetic databases that provide a powerful resource for effective recruitment into clinical trials and other research studies. Our highly regarded Movement Disorders Fellowship Training Program has trained numerous physicians and researchers, many of whom have become internationally recognized leaders in the field of movement disorders. The National Parkinson Foundation, Tourette Syndrome Association and the Huntington's Disease Society of America have recognized the accomplishments of the PDCMDC by selecting it as one of their respective Centers of Excellence.


PDCMDC DATABASE

Diagnosis	Percent (N = 34,274)
Parkinsonism	33.7
Parkinson's disease	25.1
Other parkinsonian disorders (including PSP, MSA, CBS, vascular, DIP, etc.)	8.6
Dystonia (including cervical, cranial, etc.)	17.7
Tremor (including ET)	16.6
Tics (including TS)	8.2
Psychogenic (functional)	4.2
Chorea (including HD)	3.2
Restless legs syndrome	3.1
Tardive dyskinesia	2.4
Myoclonus	2.2
Hemifacial spasm	1.7
Ataxia	1.6
Other (gait disorders, spasticity, ballism, stereotypies, paroxysmal dyskinesias, etc.)	5.4

TEXAS MEDICAL CENTER



In January, 2015 the PDCMDC relocated to a new home at the Baylor St. Luke's Medical Center, McNair Campus, 7200 Cambridge St., 9th Fl., Houston, Texas 77030. Located on the east side of the Texas Medical Center, the world's largest medical center, the PDCMDC and other neurology clinics, along with neurosurgery and otolaryngology, are in a new state-of-the-art facility designed as an ideal setting for delivery of the most optimal, multidisciplinary patient care, cutting edge clinical research, and for training a new generation of clinicians, academicians, and researchers.



CLINICAL / BASIC RESEARCH

In addition to our primary mission to provide the most professional and compassionate patient care, we also have an active clinical research program. Leveraging Baylor's premier status in genetic research, we have intensified our research into the genetic mechanisms of Parkinson's disease (PD), essential tremor, dystonia and other movement disorders. We are also participating in numerous investigator-initiated and multicenter collaborative studies. We are one of very few centers selected to study a novel immunotherapy with antibodies targeting α -synuclein, the toxic protein that abnormally accumulates and spreads in the brains of patients with PD. We are also investigating novel delivery techniques, such as inhalable levodopa. Other clinical trials in PD are designed to test new drugs that control levodopa-related dyskinesias, PD-related dementia, autonomic dysfunction, and gait abnormalities. In addition we are involved in a clinical, imaging, and genetic PD biomarker research program sponsored by The Michael J. Fox Foundation for Parkinson's Research. We are also exploring various strategies to slow or prevent the progression of the disease and to explore novel neurophysiological concepts designed to further improve outcomes of our deep brain stimulation program. In addition to PD, we are actively involved in experimental therapeutics of other diseases, such as dystonia, tremors, Huntington disease, and Tourette syndrome.

The PDCMDC is also world renowned for its basic and translational science research, conducted at the Laboratory for Integrative Functional Genomics in the Duncan Neurological Research Institute.

Scan to download poster



COMMUNITY OUTREACH



PD Unity Walk in New York City's Central Park



Jankovic and Hunter



Tourette Camp 2017



TS Symposia 2017



Center Staff 2017



PD Caregiver Conference



Aspen Fellows Lunch, 2016



Aspen Meeting



Team HAPS 5K 2017



Tourette Camp 2017